Capital Advisors Inc. OK Reduces Position in Edwards Lifesciences Co. (NYSE:EW)

Capital Advisors Inc. OK trimmed its holdings in Edwards Lifesciences Co. (NYSE:EW) by 45.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,932 shares of the medical research company’s stock after selling 4,887 shares during the quarter. Capital Advisors Inc. OK’s holdings in Edwards Lifesciences were worth $439,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of EW. Wellington Management Group LLP boosted its position in shares of Edwards Lifesciences by 86.3% during the 3rd quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock valued at $2,080,845,000 after acquiring an additional 14,610,123 shares during the last quarter. Jennison Associates LLC acquired a new position in Edwards Lifesciences in the 4th quarter valued at about $555,939,000. Assenagon Asset Management S.A. grew its stake in shares of Edwards Lifesciences by 475.8% in the 4th quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company’s stock valued at $314,182,000 after buying an additional 3,506,886 shares during the period. Jacobs Levy Equity Management Inc. increased its holdings in shares of Edwards Lifesciences by 239.9% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 3,693,663 shares of the medical research company’s stock worth $243,745,000 after buying an additional 2,606,950 shares during the last quarter. Finally, Seilern Investment Management Ltd acquired a new stake in shares of Edwards Lifesciences during the 4th quarter worth approximately $109,490,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

EW has been the subject of several recent analyst reports. Royal Bank of Canada reissued an “outperform” rating and set a $85.00 target price on shares of Edwards Lifesciences in a research note on Wednesday. Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $82.00 to $90.00 in a research report on Monday, December 16th. Piper Sandler boosted their price objective on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a report on Wednesday. Stifel Nicolaus raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and increased their target price for the stock from $75.00 to $90.00 in a research note on Thursday, January 30th. Finally, Barclays boosted their price target on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the company an “overweight” rating in a research note on Monday, December 2nd. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Edwards Lifesciences presently has an average rating of “Hold” and a consensus target price of $79.71.

Insider Activity

In other news, VP Daniel J. Lippis sold 500 shares of the company’s stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the transaction, the vice president now directly owns 23,189 shares of the company’s stock, valued at approximately $1,594,475.64. This represents a 2.11 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $75.83 on Thursday. The stock’s 50-day moving average is $72.47 and its two-hundred day moving average is $69.32. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The company has a market cap of $44.72 billion, a price-to-earnings ratio of 10.94, a price-to-earnings-growth ratio of 3.64 and a beta of 1.10. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. Analysts forecast that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.